Media.Player

Methods to Predict Efficacy of Cancer Stem Cell Targeted Therapy (SD2012-084)

技术优势

• Compatible with nanofluidic proteomic assays, which enable automated and more sensitive detection of isoform variants• Novel biomarkers of response in validated primary cancer stem cell populations• Can confirm mechanism of action and synergistic activity (i.e. JAK2 and BCR-ABL inhibitors)• Uses both protein and confirmatory nucleic acid readouts to decrease the likelihood of false negative and false positive results.

技术应用

The pattern of alternatively spliced JAK2 and STAT5A RNA isoforms as well as their protein products can be used to: measure the effectiveness of a therapy targeting leukemic stem cells (LSC);predict or monitor which patients will be most responsive to targeted agents; assess the resistance, or relative resistance, of self-renewing LSC; andDistinguish leukemic progenitors from their normal counterparts.

详细技术说明

UC researchers have found that the extent of JAK2 and STAT5A phosphorylation as well as the RNA isoform patterns indicate the extent of response to selective JAK2 inhibition and can also be used to inform the clinician whether this therapeutic approach is likely to succeed.

*Abstract

As evidenced by fusions found in leukemia and mutations implicated in a number of myeloproliferative disorders, the JAK2 (Janus Kinase 2) gene figures prominently in blood cell development. In leukemia, it appears that JAK2 activation of Stat5A is required for tumorigenisis. In diseases with aberrant JAK2 expression or mutations, JAK2 inhibitors can be used to modulate the survival or differentiation of the affected cell population. UC researchers have explored the interaction of JAK2 and STAT5A to identify a set of markers that can be used for prognosis and monitoring of patients who may be treated with JAK2 inhibitors.

*IP Issue Date

Apr 4, 2017

*Principal Investigation

Name: Christian Barrett

Department:

Name: Kelly Frazer

Department:

Name: Catriona Jamieson

Department:

Name: Qingfei (Fay) Jiang

Department:

Name: Leslie Robertson

Department:

Name: Angela Court

Department:

Name: Anil Sadarangani

Department:

附加资料

Inventor: Safavy, Ahmad
Priority Number: US6191290B1
IPC Current: A61K004748
US Class: 549510 | 549511 | 514449
Assignee Applicant: UAB Research Foundation,Birmingham
Title: Taxane derivatives for targeted therapy of cancer
Usefulness: Taxane derivatives for targeted therapy of cancer
Summary: (I) are useful in the treatment of breast and ovarian cancer, as well as skin, lung, head and neck carcinomas (claimed).
Novelty: New soluble tumor-directed paclitaxel derivatives are useful in the treatment of breast and ovarian cancer, skin, lung, head and neck carcinomas

主要类别

诊断/治疗

细分类别

癌症/肿瘤

申请号码

9611330

其他

State Of Development

The invention has been validated in humanized murine models of CML (LSC engrafted RAG2-/-c-/- mice) using a JAK2 inhibitor (SAR302503), which is currently in clinical trials. Nanoproteomic analysis confirmed that phospho-JAK2 and phospho-STAT5A distinguished leukemic progenitors from their normal counterparts and analysis of isoforms has identified useful RNA biomarkers. Interestingly, synergistic inhibition of self-renewal isoforms was found for combination treatment using SAR302503 and dasatinib (a BCR-ABL inhibitor).

Intellectual Property Info

Worldwide rights available for licensure (See WO2013036867)

Related Materials

Fan, Alice C., et al., (2009) Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clincal specimens, Nature Medicine, 15( 5): 566-571
O'Neill, Roger A., et al., (2006) Isoelectric focusing technology quantifies protein signaling in 25 cells, PNAS, 103(44): 16153-16158
Jiang, Q. et al., (2012) ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia, Proc Natl Acad Sci U S A., (3):1041-6
also see: http://hem-onc.ucsd.edu/faculty/jamieson.shtml

Tech ID/UC Case

22588/2012-037-2

Related Cases

2012-037-2, 2012-084-0

国家/地区

美国